• Affiliate Associate Professor, Global Health
  • VP, Formulations

Seattle, WA
United States

Phone Number: 
206-858-6027
Select from the following:
Biography 

Dr. Christopher Fox leads the development of vaccine adjuvant formulations for clinical testing against a variety of infectious diseases. Since joining AAHI in 2007, he has served as Principal Investigator on multiple vaccine development grants and contracts involving pragmatic solutions to ensure equitably accessible products, such as temperature-stable formulations, intranasally administered vaccines, manufacturing process scale-up, and sustainable raw material sourcing. Dr. Fox also directs AAHI’s efforts to transfer adjuvant formulation manufacturing know-how and processes around the world to build local capacity. With 20 years of experience and over 100 publications, he is a recognized expert in the field.

Education 
  • PhD, University of Utah
  • BS, Utah State University
Country Affiliations 
Languages 
  • Spanish
Health Topics 
  • Biodefense Infectious Diseases
  • COVID-19
  • Delivery Logistics
  • Diarrheal Diseases
  • Drug and Vaccine Development
  • Education and Training
  • Immunizations
  • Infectious Diseases
  • Influenza
  • Innate Immunity
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • Pharmaceutical Science
  • Respiratory Disease
  • TB
  • Viruses
  • Waterborne Diseases
  • Zoonotic Diseases and Animal Health
DGH Centers, Programs and Initiatives and Affiliated Organizations 
Publications 

Abhyankar MM, Orr MT, Kinsey R, Sivananthan S, Nafziger AJ, Oakland DN, Young MK, Farr L, Uddin MJ, Leslie JL, Burgess SL, Liang H, De Lima I, Larson E, Guderian JA, Lin S, Kahn A, Ghosh P, Reed S, Tomai MA, Pedersen K, Petri WA Jr, Fox CB. “Optimizing a multi-component intranasal Entamoeba histolytica vaccine formulation using a design of experiments strategy,” Frontiers in Immunology, 2021, 12:683157.

Gomez M, Ahmed M, Das S, McCollum J, Mellett L, Swanson R, Gupta A, Carrigy NB, Wang H, Barona D, Bachchhav S, Gerhardt A, Press C, Archer MC, Liang H, Seydoux E, Kramer RM, Kuehl PJ, Vehring R, Khader SA, Fox CB. “Development and testing of a spray-dried tuberculosis vaccine candidate in a mouse model,” Frontiers in Pharmacology, 2022, 12:799034.

Methods in Molecular Biology: Vaccine Adjuvants; Fox, C. B., Editor; Springer, New York, 2017.

Fox, C. B.; Orr, M. T.; Van Hoeven, N.; Parker, S. C.; Mikasa, T. J.; Phan, T.; Beebe, E. A.; Nana, G. I.; Joshi, S. W.; Tomai, M. A.; Elvecrog, J.; Fouts, T. R.; Reed, S. G. “Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach,” Journal of Controlled Release, 2016, 244:98-107.

Key roles of adjuvants in modern vaccines. Reed SG, Orr MT, Fox CB. Nat Med. 2013 Dec;19(12):1597-608.